Case Report: Bortezomib Plus CDOP Followed by Sequential Autologous Hematopoietic Stem Cell Transplantation and Lenalidomide-Based Maintenance Therapy in Plasmablastic Lymphoma

The standardized treatment plan for patients with plasmablastic lymphoma (PBL) remains controversial. Taking morphological characteristics and immunophenotypes into consideration may provide superior options for the treatment of PBL. In this case, we report that a myeloma-type regimen containing bor...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in medicine 2021-12, Vol.8, p.749863
Main Authors: Cai, Jiao, Qiu, Ling, Ma, Lei, Zhang, Nan, Fan, Fang-Yi
Format: Article
Language:English
Subjects:
18F-FDG PET/CT
autologous hematopoietic stem cell transplantation
bortezomib
lenalidomide
Medicine
plasmablastic lymphoma
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The standardized treatment plan for patients with plasmablastic lymphoma (PBL) remains controversial. Taking morphological characteristics and immunophenotypes into consideration may provide superior options for the treatment of PBL. In this case, we report that a myeloma-type regimen containing bortezomib plus cyclophosphamide, epirubicin, vindesine and prednisolone (CDOP) followed by sequential autologous hematopoietic stem cell transplantation (ASCT) and lenalidomide-based maintenance therapy to treat PBL may represent a promising regimen to improve the prognosis.
ISSN:2296-858X
2296-858X
DOI:10.3389/fmed.2021.749863